Specific Characteristic of Hyperplastic Callus in a Larger Cohort of Osteogenesis Imperfecta Type V

Calcif Tissue Int. 2022 Apr;110(4):451-463. doi: 10.1007/s00223-021-00932-2. Epub 2022 Jan 6.

Abstract

Hyperplastic callus (HPC) is the most conspicuous features of osteogenesis imperfecta (OI) type V, of which accurate diagnosis and treatment are facing challenges. We investigate the clinical features, and impact factors of HPC in OI type V patients. In this retrospective single-center study, a total of 21 patients with type V OI confirmed by IFITM5 mutation were included. Radiological characteristics of bone were evaluated by X-rays, dual-energy X-ray absorptiometry, and computed tomography scan. Bone biopsy specimens were performed and stained by routine hematoxylin-eosin. The effects of bisphosphonates on HPC were investigated. Eleven patients (52.3%) had HPCs at 19 skeletal sites, 11 of which affected the femur. Three patients developed four (21.1%) HPCs after fractures, and 15 (78.9%) HPCs occurred in absence of bone fracture. The progress of HPCs was variable, of which most HPCs enlarged in the initial phase and remained stable, and only one HPC dwindled in size. One patient had a rapidly growing mass on the right humerus, and biopsy showed irregular trabeculae of woven bone and immature bone and cartilage in the loose and edematous collagenous network without signs of tumor. Bisphosphonates treatment had no significant effects on HPC of OI patients. HPC is the specific characteristic of OI type V patients, and its location, shape, size, and progression are variable, and the femur is the most frequently involved site. It is very important to make a diagnosis of HPC through detecting IFITM5 mutation and completing pathological diagnosis if necessary. The treatment of HPC is worth further exploration.

Keywords: Hyperplastic callus formation; IFITM5; Osteogenesis imperfecta type V; Osteosarcoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diphosphonates / therapeutic use
  • Humans
  • Membrane Proteins / genetics
  • Osteogenesis Imperfecta* / drug therapy
  • Retrospective Studies

Substances

  • Diphosphonates
  • Membrane Proteins

Supplementary concepts

  • Osteogenesis Imperfecta, Type V